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 I NTRODUCTION :  Antimicrobial resistance is a growing concern with implications for animal health. This 
study investigated the prevalence of antimicrobial resistance among commensal and environmental 
 Escherichia coli isolated from animals sampled in referral hospitals in the  UK . 
 M ATERIALS AND M ETHODS :  Resistant  Escherichia coli isolated from animal faeces and practice environments 
were tested for susceptibility to antimicrobial agents.  PCR and sequencing techniques were used to 
identify extended spectrum beta-lactamase and  AmpC -producer genotypes. 
 R ESULTS :  In total, 333 faecal and 257 environmental samples were collected. Multi-drug resistant  Escherichia 
coli were found in 13·1% of faecal and 8·9% of environmental samples. Extended spectrum beta-lactamase 
and  AmpC genes were identified 14% and 7·7% of faecal samples and 8·6% and 8·6% of environmental 
samples, respectively. The most common extended spectrum beta-lactamase gene type detected was 
 bla CTX-M −15 , although  bla TEM-158 was detected in faecal and environmental samples from one practice. 
 C LINICAL S IGNIFICANCE :  Escherichia coli resistant to key antimicrobials were isolated from hospitalised 
animals and the practice environment. We identified the emergence of the inhibitor resistant and 
extended spectrum beta-lactamase  bla TEM-158 in companion animals. Further investigation to determine 
risk factors for colonisation with antimicrobial-resistant bacteria is needed to provide evidence for 
antimicrobial stewardship and infection control programmes. 
 I. Tuerena’s current address is Manchester, M15 5TQ 
 T. Nuttall ’ s current address is Royal (Dick) School of Veterinary Studies, University of Edinburgh, 
Easter Bush Campus, Roslin, Edinburgh, EH25 9RG 
 INTRODUCTION 
 Antimicrobial resistance has the potential for major impact on 
animal welfare, limiting therapeutic options. Antimicrobial resis-
tant (AMR) infections can increase morbidity and mortality and, 
furthermore, have been shown to be associated with an increased 
financial burden in human (Baker  et al.  2012 , Smith & Coast 
 2013 , Tansarli  et al.  2013 ) and veterinary (Dallap Schaer  et al. 
 2010 ) medicine. 
 Humans, dogs and other mammals carry commensal  Esch-
erichia coli ( E .  coli ) within the gut where exposure to antimi-
crobial agents can select for resistance. Antimicrobial resistance 
in  E .  coli isolates from companion animals has been reported 
in both healthy dogs in the community (Carattoli  et al.  2005 , 
Sun  et al.  2010 , Wedley  et al.  2011 , Franiek  et al.  2012 , Tamang 
 et al.  2012 , Ben Sallem  et al.  2013 , Gandolfi-Decristophoris  et al. 
 2013 ) and hospitalised animals (So  et al.  2012 ). However, AMR 
burdens may be higher in hospitalised animals (Nam  et al.  2010 ) 
and in animals undergoing treatment (Sun  et al.  2010 ) compared 
to healthy animals. One AMR mechanism of importance among 
 E .  coli is the production of beta-lactamases (Sykes &  Matthew 
 1976 ). Use of third and fourth generation  cephalosporins has 
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contributed to the emergence of extended spectrum beta-
lactamase (ESBL) enzymes (Pfeifer  et al.  2010 ), which confer 
resistance to all beta-lactam antibiotics, although they remain 
sensitive to beta-lactamase inhibitors, such as clavulanic acid. 
 E .  coli can also gain resistance to beta-lactam agents by the 
production of cephamycinase AmpC enzymes which, unlike 
ESBLs, also confer resistance to beta-lactamase inhibitors. In 
addition, ESBL genes frequently co-exist with other resistance 
genes on the same plasmid, resulting in resistance to multiple 
antimicrobial classes (Woodford  et al.  2004 , Pitout  et al.  2007 , 
Pitout & Laupland  2008 , Schultsz & Geerlings  2012 ). This adds 
to the resistance burden within bacterial populations, because the 
use of one antimicrobial class could select for resistance to mul-
tiple other classes by favouring the spread of plasmids that confer 
multi-drug resistance (MDR – resistance to ≥three drug classes). 
 Antimicrobial-resistant  E .  coli have been isolated from faeces 
of animals in many parts of the world. Moreover, ESBL-pro-
ducing bacteria have been associated with urinary tract infec-
tions (O ’ Keefe  et al.  2010 , Shaheen  et al.  2011 , Dierikx  et al. 
 2012 , Huber  et al.  2013 , Nebbia  et al.  2014 ), wound infections 
(Steen & Webb  2007 ) and cholangiohepatitis in companion 
animals (Steen & Webb  2007 , Timofte  et al.  2011 ). Among 
ESBL-producing isolates from studies of companion animals 
the most common types of ESBLs identified have been CTX-M 
types (Carattoli  et al.  2005 , Sun  et al.  2010 , Dierikx  et al.  2012 , 
Tamang  et al.  2012 , Ben Sallem  et al.  2013 , Huber  et al.  2013 ). 
However, data on the frequency and epidemiology of these bacte-
ria within veterinary environments in the UK are lacking. 
 Therefore, the aim of this study was to determine the preva-
lence of important AMR  E .  coli phenotypes and genotypes in the 
faecal flora of hospitalised animals and the hospital environment 
in referral practices in the UK. This included resistance to antimi-
crobials critically important to human health (WHO  2011 ), such 
as the third and fourth generation cephalosporins and fluoroqui-
nolones, which are also important in companion animals, as well 
as resistance to commonly used antimicrobials in companion ani-
mals, such as clavulanic acid-potentiated amoxicillin and potenti-
ated sulphonamides. In addition, we aimed to characterise and 
compare the genes associated with ESBL-producing and AmpC-
producing  E .  coli in the environment and shed in faeces. 
 MATERIALS AND METHODS 
 Practice selection and sample collection 
 Five referral hospitals in Northwest UK took part in the study. 
The main inclusion criterion was that the hospital must accept 
secondary referral patients, including cases likely to be hospital-
ised. The limitation to the Northwest region was to facilitate the 
sample collection and minimise time between collection and lab-
oratory processing. Written informed consent was obtained from 
all owners whose animals took part in the study. Ethical approval 
was granted by the University Research Ethics Committee. Sam-
ple size estimates indicated that with an expected prevalence of 
ESBL-producing  E .  coli of 10%, 385 faecal samples would be 
required to determine the prevalence with a precision of 3 and 
95% confidence. Hence the aim was to collect 385 animal faecal 
samples in addition to the environmental samples. 
 Animals eligible for the study were all dogs and cats hospitalised 
for at least one night in the practice. Day cases were excluded as 
were animals receiving chemotherapy or radiotherapy and those in 
isolation. The target for sample collection was one faecal sample per 
hospitalised animal per day. Samples were collected by practice staff, 
stored in cool-boxes at the practice and collected at regular intervals. 
 Sampling was rotated and performed in three blocks of 2 weeks 
at each practice apart from one practice that included an extra pilot 
week. Environmental samples were collected by the author weekly 
once during each week of sampling from each practice. There was 
some variation in the exact sites selected for weekly sampling in 
each practice necessitated by the different layouts. However, the 
areas sampled from all practices were: ward floors; computer key-
boards in kennel rooms and treatment areas; examination tables 
in treatment areas (not in consulting rooms); and the outside dog 
walking areas. If there were multiple keyboards or examination 
tables in the same area, one was selected on the first week of sam-
pling and was used for all subsequent sample collection. Samples 
from floors were collected by wearing sterile disposable absorbent 
overshoes (boot socks) moistened with 2 to 3 mL sterile saline, 
walked around rooms in the same pattern each week. Samples were 
taken from keyboards and tables using sterile j-clothes that are cut 
to a standard size (~15 cm 2 ), moistened with sterile saline and used 
to wipe over the entire surface of keyboards and tables. 
 Isolation of resistant bacteria from faecal and 
environmental samples 
 Samples were transported to the laboratory of  University of 
 Liverpool and processed immediately after collection. For faeces, 
2 g was homogenised in brain heart infusion broth and used to 
inoculate the entire surface of an eosin methylene blue agar plate 
(EMBA). Antibiotic discs impregnated with ampicillin (10 µg), 
clavulanic acid potentiated amoxicillin (Augmentin®; potenti-
ated amoxicillin, 30 µg), ciprofloxacin (1 µg) and trimethoprim 
(2·5 µg) were added to the plate, which was then incubated over-
night at 37°C (Bartoloni  et al.  2006 ). A 0·5-mL aliquot of the 
faecal homogenate was added to 4·5-mL buffered peptone water 
and incubated over night at 37°C before processing as below. 
 Boot socks and cloths were agitated in 20-mL buffered pep-
tone water for 2 minutes and a 10-mL aliquot incubated over-
night at 37°C. After overnight incubation environmental samples 
were processed as below. 
 The faecal and environmental homogenates after overnight 
enrichment were streaked onto 1 EMBA plate containing 1 µg/mL 
cefotaxime and another containing 1 µg/mL ceftazidime to isolate 
cephalosporin-resistant  E .  coli , and incubated overnight at 37°C. 
 A maximum of six potential AMR  E .  coli isolates could be 
selected per faecal sample if present: one each from the four 
inhibition zones on the plate containing antimicrobial discs, one 
from each of the cephalosporin-impregnated EMBA plates. Each 
environmental sample yielded a maximum of two isolates if typi-
cal growth was present on the cephalosporin-impregnated plates. 
All isolates were then subjected to full antimicrobial susceptibil-
ity testing as detailed below. 
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 Antimicrobial susceptibility and ESBL phenotypic 
testing 
 Full susceptibility testing was performed on all isolates using iso-
sensitest agar (LabM, UK) with discs impregnated with 10-µg 
ampicillin, 30-µg potentiated amoxicillin, 30-µg chloramphenicol, 
30-µg nalidixic acid, 1-µg ciprofloxacin, 2·5-µg trimethoprim and 
30-µg tetracycline, according to BSAC guidelines (BSAC  2013 ). 
 Isolates from the ceftazidime and cefotaxime EMBA plates, 
or which were resistant to CAPA, were also tested for ESBL 
phenotypes and AmpC phenotypes using the Mast Ltd (Bootle, 
UK) double disc set according to the manufacturer ’ s instructions 
(M ’ Zali  et al.  2000 ), which has been found to have 90% sensitiv-
ity and specificity for the detection of AmpC-producer pheno-
types (Ingram  et al.  2011 ). 
 All antibiotic discs were obtained from Mast Ltd, the antibi-
otic powders from Sigma–Aldrich UK and all media from Lab M 
Ltd (Bury, UK). 
 Genotypic analysis 
 Cell lysates were prepared by adding two to three colonies of pure 
24-hour cultures to 0·5 mL sterile water and heating at 100°C 
for 20 minutes. All isolates morphologically consistent with  E . 
 coli were confirmed using  uidA gene primers (McDaniels  et al. 
 1996 , Maddox  et al.  2011 ). All isolates demonstrating resistance 
to cefotaxime and ceftazidime on sensitivity testing were tested 
for  bla 
CTX
 
-M
 genes using universal  bla 
CTX-M
 primers as previously 
described (Batchelor  et al.  2005 ). To determine the CTX-M 
group produced, all CTX-M positive isolates were tested using 
primers specific to  bla 
CTX-M
 groups 1, 2(Hopkins  et al.  2006 ) 
and 9 (Batchelor  et al.  2005 ). All isolates identified as producing 
CTX-M group 1 ESBLs were tested to further determine whether 
they belonged to serogroup O25 (Clermont  et al.  2008 ) and for 
markers for sequence type (ST) 131 (Clermont  et al.  2009 ), rep-
resenting the pandemic  E .  coli clone associated with  bla 
CTX-M-15 in
 
human clinical infections (Lau  et al.  2008 ) 
 All isolates demonstrating ceftazidime resistance on sensitivity 
testing were also tested for  bla 
TEM
 ,  bla 
SHV
 and  bla 
OXA
 genes using 
a further multiplex PCR assay (Dallenne  et al.  2010 ). All isolates 
demonstrating potentiated amoxicillin resistance on sensitivity 
testing were tested for  bla 
CITM
 using CITM primers (Perez-Perez 
& Hanson  2002 ). The specific genotypes of beta-lactamase genes 
( bla 
CTX-M
 ,  bla 
TEM
 ,  bla 
CMY
 ) were further determined with gene 
amplicons sequenced (Perez-Perez & Hanson  2002 , Boyd  et al. 
 2004 , Batchelor  et al.  2005 ) at the Zoology Sequencing Facil-
ity, University of Oxford. The specific genes were determined 
by comparing the sequences with those submitted to GenBank 
( http://www.ncbi.nlm.nih.gov/genbank ). 
 All isolates demonstrating quinolone resistance were tested for 
the presence of the plasmid-mediated quinolone resistance genes, 
 qnrA ,  qnrB and  qnrS using a multiplex PCR assay as previously 
described (Robicsek  et al.  2006 ). 
 Statistical analysis 
 Descriptive statistics and 95% confidence intervals were calcu-
lated for overall prevalence and for each practice. Resistance to 
each antimicrobial was considered as a separate outcome. The 
other outcomes considered were: MDR  E .  coli ; resistance to third 
generation cephalosporins; and ESBL- and AmpC-producer phe-
notypes and genotypes. 
 Data were clustered within veterinary practices and, because 
of repeated sampling, also within animal, so to obtain accurate 
estimates after allowing for this clustering the prevalence of AMR 
 E .  coli was estimated using multilevel, binomial models for each 
outcome, with practice and dog clustering accounted for by 
incorporation of second- and third-level random intercept terms. 
Calculations were performed using penalised quasi-likelihood 
estimates (second- order or first-order PQL). The prevalence (P 
T
 ) 
was estimated using the formula below, incorporating the con-
stant parameter estimate ( β 
0
 ) derived from the random intercept-
only 3-level models for each outcome considered: 
  PT = eβ0/1 + eβ0 
 95% confidence intervals for all adjusted prevalence estimates 
were constructed by examination of the standard errors of the 
intercept-only model parameters. Data were analysed using the 
MLwiN statistical software package (MLwiN Version 2.1 Centre 
for Multilevel Modelling, University of Bristol, UK). 
 RESULTS 
 A total of 333 faecal samples were collected from 214 ani-
mals over 31 sampling weeks between May 13 and October 
21, 2013 (Table  1 ). In total 348/363 faecal isolates and 77/86 
 Table 1 .  Total number of faecal and environmental samples collected for each practice. Faecal samples are categorised 
by species and environmental samples by location 
Faecal samples * Environmental samples † 
Practice Dogs Cats Not specified Total Inside floors Examination tables Keyboards Outdoors walking area Total 
1 122 14 0 136 28 12 18 7 65 
2 32 0 5 37 30 6 6 6 48 
3 63 10 0 73 24 6 12 6 48 
4 34 0 2 36 24 6 12 6 48 
5 45 0 6 51 30 6 6 6 48 
Total 296 24 13 333 136 36 54 31 257
 * This included repeated samples from animals. The median number of samples per animal was 2 (interquartile range 1 to 3) and ranged from a minimum of 1 to a maximum of 14 
 † Environmental samples were collected by the author once weekly during each week of sampling, and the sites sampled were selected at the beginning of the study and remained 
constant. All hospitals were sampled for 6 weeks except for hospital 1 which had an additional pilot week 
I. Tuerena et al.
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 environmental isolates tested positive using the  uidA PCR test 
confirming the  E .  coli identity of these isolates. 
 E .  coli resistant to at least one antimicrobial were isolated from 
167/333 (50·1%) faecal samples. A total of 257 environmen-
tal samples were collected during the same 31 sampling weeks 
(Table  1 ). Of these, 47 (18·3%) contained AMR  E .  coli cultured 
from cephalosporin selective plates. 
 The overall prevalence of faecal and environmental samples 
with at least one isolate with resistance to one or more of the six 
antimicrobials, to third generation cephalosporins, MDR, and 
ESBL-producer and AmpC-producer phenotypes, and ESBL and 
 bla 
CITM
 genotpyes is shown in Tables  2 and  3 . Ampicillin resis-
tance was the most common resistance type in both faecal and 
environmental samples. 
 There was considerable variation in the rate of isolation of 
resistant bacteria between practices and between areas within 
practices (Fig  1 , and Tables  2 and  3 ). Practice 1 demonstrated the 
highest prevalence of potentiated amoxicillin resistance, cipro-
floxacin resistance, and AmpC-phenotype and genotype [ bla 
AmpC
 
(CITM)] in both faecal and environmental samples. Practice 3 
demonstrated the highest prevalence of ESBL-phenotype and 
genotype, and MDR  E . coli among samples. Practices 2 and 5 
generally demonstrated lower levels of resistance. The resistance 
spectrum varied among the MDR isolates from both faecal and 
environmental samples (Table  4 ). There were 18 distinct phe-
notypes among MDR isolates, 17 in the faecal samples and 10 
in the environmental samples (although there was substantial 
overlap). The diversity of  E .  coli MDR phenotypes from envi-
ronmental samples may have been limited due to isolation only 
on cephalosporin-containing media following enrichment with 
only two possible colony picks per sample, unlike faecal samples 
where up to six colony picks could be obtained. Many MDR iso-
lates were resistant to ciprofloxacin and potentiated amoxicillin. 
Environmental samples associated with ESBL-, AmpC-produc-
ing and MDR  E .  coli were most likely to be isolated from either 
the outside walking areas, or floors of the ward communal areas 
(Fig  1 ). 
 PCR detected  bla 
CTX-M
 genes belonging to group 1 in  E .  coli 
from 22 (6·6%) faecal samples from four out of five practices 
and 12 (4·7%) environmental samples from three out of five 
practices. Group 9  bla 
CTX-M
 genes were detected in  E .  coli from 3 
(0·9%) faecal samples and 2 (0·8%) environmental samples, all 
of which were from the same practice. No isolates were positive 
for CTX-M group 2, or found to belong to O25/ST131 clones 
by PCR assay. 
 The  bla 
CITM
 gene was detected in  E .  coli from 72 (21·6%) 
faecal and 22 (8·6%) environmental samples, all of which were 
shown by sequence analysis to correspond to  bla 
cmy-2
 .  This corre-
sponded to 81% and 69% of faecal and environmental samples 
with  E .  coli with potentiated amoxicillin resistance, respectively. 
There was significant masking of ESBL producer phenotype by 
the production of AmpC with  E .  coli from 20 faecal samples 
and 2 environmental samples that had both AmpC and ESBL 
genes. 
 A low prevalence of  qnr genes was found only in three (1%) 
faecal samples having at least one  E .  coli isolate which tested 
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 There was frequent potentiated-amoxicillin resistance among 
samples from all the practices, with an adjusted prevalence of 
14% (albeit with some variation between practices). Potentiated 
amoxicillin is commonly used in companion animal practice 
in the UK (Mateus  et al.  2011 , Radford  et al.  2011 ) and the 
frequent carriage of resistance is likely related to the frequency 
of use. Nevertheless, this is of some concern. In human medi-
cine the prevalence of ESBLs in hospitals has been linked to use 
of potentiated amoxicillin in the community, highlighting the 
importance of interaction between community antimicrobial use 
and the development of AMR in hospitals (Aldeyab  et al.  2012 ). 
Resistance to potentiated amoxicillin has been found in dogs 
in other studies, but at lower levels ranging from 6·3 to 8·3%. 
The high levels in this study are likely to reflect hospitalisation, 
because a study of non-vet visiting dogs in a similar area showed a 
relatively low level of potentiated amoxicillin resistance (Wedley 
 et al.  2011 ). 
 The majority of  E .  coli with potentiated-amoxicillin resistance 
tested positive for  bla 
AmpC
 genes, making AmpC production the 
most likely mechanism responsible for resistance. AmpC genes 
conferring AmpC production have also been found in clinical 
 E .  coli isolates from animals in the USA (Shaheen  et al.  2011 ) 
and the Netherlands (Dierikx  et al.  2012 ), and in hospitalised 
animals in Korea (So  et al.  2012 ) and Australia (Sidjabat  et al. 
 2006 ). High levels of AmpC-production have been found in a 
human healthcare setting where they were putatively linked with 
a high use of potentiated-amoxicillin in the same facility (Sei-
ffert  et al.  2013 ). These results suggest that AmpC-production 
is potentially an important mechanism conferring potentiated-
amoxicillin resistance among hospitalised companion animals. 
 Potentiated-amoxicillin resistance and AmpC genes were 
found in environmental samples from all practices, although 
there was variation between practices, which followed a simi-
lar pattern to that seen in the faecal samples, suggesting a link 
between commensal faecal and environmental-resistant  E .  coli . 
Colonisation of dogs and humans and contamination of the vet-
erinary environment by the same AmpC-producing  E .  coli strains 
has been reported previously (Sidjabat  et al.  2006 ) and the envi-
ronmental prevalence (4·1%) reported is similar to levels found 
in most of the practices in this study. 
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 FIG 1 .  The percentage of samples from each area within each practice yielding an isolate positive for multi-drug resistance, extended spectrum 
beta-lactamase or AmpC-producer phenotypes. Y-axis represents the percentage of all samples collected from that area that showed the resistance 
phenotype (±95% confidence intervals) 
 Table 5 .  Number and percentage of faecal (n=333) 
and environmental (n=257) samples with at least 
one  Escherichia coli isolate having a resistance gene 
identified by sequence analysis 
Gene
Faecal samples Environmental samples
N % (95% CI) N % (95% CI) 
 bla  CTX-M-15  
* † 20 6 (3·5 to 8·6) 8 3·1 (1 to 5·2) 
 bla  CTX-M-1  1 0·3 (0 to 0·9) 1 0·4 (0 to 1·2) 
 bla  CTX-M-9  1 0·3 (0 to 0·9) 0  
 bla  CTX-M-82  1 0·3 (0 to 0·9) 0  
 bla  TEM-158  10 3 (1·2 to 4·8) 1 0·4 (0 to 1·2) 
 bla  SHV-12  0 2 0·8 (0 to 1·9) 
 bla  CMY-2  
‡ 72 21·6 (17·2 to 26·0) 22 8·6 (5·1 to 12·0)
 * In five isolates positive on the universal  bla CTX-M PCR the group was not identified 
 † Groups 1 and 9  bla CTX-M were detected in isolates by PCR but sequence analysis could 
not confirm the individual gene they carried belonging to these groups in five samples 
 ‡ All  citm positive isolates that returned a result on sequence analysis corresponded to 
 bla CMY-2 
 positive for  qnr genes on PCR. Two were positive for  qnrS and 
one was positive for  qnrB . Among environmental samples isolates 
the  qnrB was detected in  E .  coli from four (1·5%) samples. 
 Interestingly, the inhibitor-resistant and ESBL variant  bla-
 
TEM-158
 was detected in  E .  coli isolated from 10 faecal samples and 
1 environmental sample, all from the same practice. 
 Sequencing results are shown in Table  5 . However, not all iso-
lates positive for beta-lactamase genes returned sequences good 
enough for analysis, and these are recorded at the gene or group 
level only (e.g. CTX-M group 1) 
 DISCUSSION 
 Overall, in isolates from both faecal and environmental sam-
ples there were relatively high levels of resistance to a number 
of important antimicrobials including potentiated amoxicillin, 
fluoroquinolones and third generation cephalosporins. This has 
important implications for clinical veterinary practice and public 
health. Steps towards mitigating this problem will first require a 
thorough understanding of the prevalence and transmission in 
patients and the practice environment. 
Antimicrobial resistance in companion animals
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 The prevalence of resistance to ciprofloxacin (a marker for 
fluoroquinolone resistance) was variable between practices, rang-
ing from 8 to 44%. In contrast, ciprofloxacin resistance was only 
found in 2·2% of community dogs using similar methods in 
the same area (Wedley  et al.  2011 ). Moreover, 73% of the 80 
faecal samples with ciprofloxacin-resistant  E .  coli demonstrated 
MDR phenotypes. Fluoroquinolones are a class of antimicrobial 
used in treatment of important infections in both human and 
veterinary medicine and are classed as a high priority antimicro-
bial (WHO  2011 ), and resistance to these drugs is a serious con-
cern for animal and public health. The frequent co-association 
of fluoroquinolone resistance with resistance to other, unrelated 
classes of antimicrobial is an additional concern. The  qnr genes 
were detected at low rates among both faecal and environmental 
samples and are therefore unlikely to be a significant contribu-
tor to the levels of quinolone resistance observed in this study. 
Further mechanisms for quinolone resistance in this study were 
not studied, but they are most likely to be due to chromosomal 
mutations in the gyrase genes. 
 The prevalence of MDR in faecal samples from this study was 
13%. The similar resistance profiles between MDR faecal and 
environmental samples are suggestive of cross contamination 
between animals and their environment. Of particular concern 
is the relatively frequent isolation of bacteria resistant to all seven 
antimicrobials tested. Other studies reported MDR in 48% in 
hospitalised dogs and 32% of stray dogs from Korea (Nam  et al. 
 2010 ), 15% of community-based dogs in the UK (Wedley  et al. 
 2011 ) and 9% of animals at admission in the USA (Hamilton 
 et al.  2013 ). It has also been shown that resistant organisms are 
more prevalent among hospitalised or sick animals compared to 
non-hospitalised or healthy animals (Nam  et al.  2010 , Sun  et al. 
 2010 , Gibson  et al.  2011 ). It is also noteworthy that the MDR 
isolates in this study frequently included resistance to potentiated 
amoxicillin and fluoroquinolones, whereas this was uncommon 
in MDR isolates from community-based dogs (Wedley  et al. 
( 2011 ), which were most frequently resistant to ampicillin, tetra-
cycline and trimethoprim. 
 Resistance to third generation cephalosporins was detected at 
relatively high rates in this study. Studies of companion animals 
have found variable levels of resistance depending on setting and 
methods used: ranging from 60·5% in hospitalised pets treated 
with antimicrobials in China (Lei  et al.  2010 ); 13% in dogs and 
cats from the community and nursing homes in Switzerland 
(Gandolfi-Decristophoris  et al.  2013 ); and 2·4% from stray and 
hospitalised dogs in Korea (Nam  et al.  2010 ). 
 The confirmed sample prevalence of ESBL-producer pheno-
types in this study was 13%. ESBL production has been detected 
in: 54·5 and 24·5% in sick and healthy animals, respectively, in 
veterinary hospitals in China (Sun  et al.  2010 ); 33·3% in Korean 
veterinary hospitals (So  et al.  2012 ); 5% of faecal samples from 
cats and dogs in shelters in Germany (Franiek  et al.  2012 ); and 
16% of faecal samples from healthy cats and dogs in Tunisia (Ben 
Sallem  et al.  2013 ). ESBLs have also been detected from clinical 
urinary isolates in the USA (O ’ Keefe  et al.  2010 , Shaheen  et al. 
 2011 ) and Switzerland (Huber  et al.  2013 ). There is clearly varia-
tion in ESBL-producer prevalence by location and setting. Hos-
pitalised animals appear to be at greater risk, though this study 
demonstrated variation among hospitals and there are likely to be 
hospital level factors that have an important influence. Assessing 
ESBL production by phenotypic results only led to an underes-
timation of the true prevalence in this study due to masking by 
AmpC-producer phenotypes in the same isolates. This was par-
ticularly of note in the practice that had high levels of AmpC pro-
duction, demonstrating the importance of production of AmpC 
not only in the resistance it confers but also in its ability to make 
detecting and confirming ESBL production more difficult. 
 The most common ESBL genotype identified in this study was 
 bla 
CTX-M-15
 . Several other studies have found CTX-M-1 produc-
tion to be more common in companion animals isolates (Costa 
 et al.  2008 , Dierikx  et al.  2012 ). However, others have identified 
 bla 
CTX-M-15
 in companion animals (Sun  et al.  2010 , Dierikx  et al. 
 2012 , So  et al.  2012 , Huber  et al.  2013 , Belas  et al.  2014 ) and in 
Europe it is the second most commonly isolated ESBL gene from 
companion animals (Ewers  et al.  2012 ). A number of ESBL-
positive samples in this study were found to carry  bla CTX-M 
genes, but these could not be assigned to a group (n=5  E .  coli ) 
or, when assigned to a group, the sequence was poor so that it 
could not be used to determine the specific  bla 
CTX-M
 gene type. 
The true prevalence of CTX-M type ESBLs may therefore be dif-
ferent. The  bla 
CTX-M-15
 gene is the most common gene associated 
with the human pandemic O25/ST131  E .  coli clone in the UK 
(Lau  et al.  2008 ); however, no  E .  coli isolates that carried  bla 
CTX-
M
 genes in this study were positive for markers for this clone. 
However, other  E .  coli clones have been isolated from companion 
animals in Europe associated with CTX-M production, such as 
ST648 (Ewers  et al.  2014 ). 
 The  bla 
TEM-158
 gene was the second most prevalent ESBL 
genotype found in this study. It was first detected from a faecal 
sample from a human intensive care patient in France and dem-
onstrates both ESBL and inhibitor resistant TEM (IRT) charac-
teristics (Robin  et al.  2007 ), and due to this is often referred to as 
a complex mutant TEM (CMT). Other studies have identified 
TEM-158 production in urinary  E .  coli isolates in the human 
community in Morocco (Barguigua  et al.  2013 ) and clinical iso-
lates from human patients in Kenya (Kiiru  et al.  2012 ). Evolution 
of TEM-158 has been shown to occur as a result of antimicro-
bial therapy in humans (Jacquier  et al.  2013 ). Occurrence of 
this beta-lactamase at relatively high levels in one hospital is of 
concern given that it confers a wider spectrum of resistance to 
beta-lactams and the fact that its inhibitor resistant characteris-
tics can make identification difficult. Molecular methods includ-
ing sequencing are required to distinguish TEM-158 production 
from that of AmpC and other ESBL variants. We are not aware 
of any other studies in companion animals that have identified 
the presence of  bla 
TEM-158.
 As the only studies reporting this previ-
ously were from humans it may be that inter-species transmission 
has occurred or, alternatively, it may have been driven by anti-
microbial therapy. Further study is needed to determine factors 
responsible for this, including examining the referring popula-
tion of animals in the community. 
 Contamination of the human hospital environment with 
ESBL-producing  Enterobacteriaceae originating from patients 
I. Tuerena et al.
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has been reported (Guet-Revillet  et al.  2012 ). Furthermore, in 
a companion animal veterinary hospital in Canada environmen-
tal contamination with  E .  coli was detected in 92% and CMY-2 
(AmpC) producing  E .  coli in 9% of the hospitals sampled (Mur-
phy  et al.  2010 ). These findings suggest that  E .  coli with impor-
tant resistance phenotypes such as EBSL and AmpC producers, 
are present in practice environments, where they may act as a 
source of infection and reservoir of resistance determinants. 
 For most practices the outside walking and toileting area were 
the areas with the most frequent isolation of resistant bacteria, 
despite practice staff picking up and disposing of faeces. Con-
tamination of this area with  E .  coli may be associated with large 
numbers of dogs, mixing from different wards and difficulty with 
disinfection of the surface. Practices 1, 2 and 5 had grassy walk-
ing areas and practice 4 had a wood chip surface, which all would 
be difficult to disinfect. Only practice 3 had a concrete surface 
that should be easier to disinfect, and the isolation rate from the 
outside area in this practice was similar to other areas within the 
practice. Internal floors were next most frequently associated with 
resistant bacteria, with tables and keyboards less commonly con-
taminated. This may be associated with effective hand hygiene 
and/or the relative ease of cleaning and disinfecting these sites. 
 One weakness of this study was the variable number of sam-
ples returned by practices because of low throughput of animals 
and a lack of hospitalised patients in some hospitals. In addition, 
for ethical reasons, only naturally-voided faecal samples were 
collected, and animals that did not defecate (e.g. when hospi-
talised for short periods or if non-ambulatory) may be under-
represented. There was also some variation in time between 
sample collection and processing, although this never exceeded 
3 days. The use of bags to collect faeces may have led to under-
representation of soft or liquid faeces, therefore diarrhoeic dogs 
may also be underrepresented. Cats were included as there have 
been no equivalent studies of their carriage of resistant bacteria, 
but the study power was limited by low numbers associated with 
less frequent hospitalisation of cats. Environmental sample col-
lection was variable as this was designed to fit around practice 
routine to minimise disruption. It is therefore possible that clean-
ing may have occurred at variable times before sample collection, 
which could have affected isolation rates of  E .  coli . Furthermore, 
only potential ESBL/AmpC producers were isolated following 
enrichment of environmental samples. Therefore, cephalospo-
rin isolation rates and phenotypes are only directly comparable 
between faecal and environmental samples. Our study also used 
methodology which specifically selected for resistant variants 
of  E .  coli , so our reported prevalence may be higher compared 
to other studies in which selective isolation was not employed. 
Nevertheless because of this our findings are likely to reflect the 
true prevalence concerning faecal carriage of resistant bacteria in 
hospitalised animals. Finally, this study was based in secondary 
and tertiary referral hospitals, and the results may not reflect first 
opinion practice. 
 In summary, this project demonstrated that important AMR, 
MDR and ESBL phenotypes and genotypes are present among 
faecal and environmental  E .  coli in veterinary hospitals, includ-
ing the detection of production of the IRT TEM-158. Such  E . 
 coli are potential pathogens (Steen & Webb  2007 , O ’ Keefe  et al. 
 2010 , Timofte  et al.  2011 , Huber  et al.  2013 , Nebbia  et al.  2014 ), 
and treatment options for infections would be limited. Moreover, 
close contact between pets and their owners (Westgarth  et al. 
 2008 ) could result in zoonotic transmission of resistant organisms 
or resistance determinants if present on mobile genetic elements. 
Contamination of the practice environment with these bacteria 
is of concern because environmental bacteria could be dissemi-
nated to new sites and animals (particularly vulnerable patients). 
They may also act as a source of infection for new animals in the 
environment and a source of resistance genes for exchange with 
previously susceptible  E .  coli . Further work is required to study 
the transmission of such resistant bacteria in companion animals 
and their practice environment, the resistance determinants and 
their mobility, and their association with virulent clones, to show 
how this contributes to clinical infections with resistant organ-
isms. Furthermore determining risk factors associated with envi-
ronmental contamination and carriage of resistant commensal  E . 
 coli and elucidating reasons for the differences between practices 
will help inform effective infection control measures and antimi-
crobial stewardship programmes. 
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